# Akka Venture

> Akka Venture is a VC fund in Paris backing Medical and Biopharma. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 2
- Last investment: Sep 2004
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/dajou
- X (Twitter): http://twitter.com/AkkaVenture
- Website: http://www.akkaventure.com
- Facebook: http://www.facebook.com/akkaventure

Akka Venture is a Paris-based growth advisory firm that provides strategic and financial services to European companies.

## Contacts

5 contacts available for Akka Venture. Shizune tracks 1 team members at Akka Venture. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/akka-venture?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 50% |
| Biopharma | 1 | 50% |
| Biotechnology | 1 | 50% |
| Pharmaceutical | 1 | 50% |
| Clinical Trials | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Series C | 1 | 50% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| David Jouarisse | Partner | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Innate Pharma | Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases.The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led tolicensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb. | $16.5M | Series C | Sep 01, 2004 |  |
| Innate Pharma | Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases.The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led tolicensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb. | $21.9M | Series B | Jan 01, 2002 |  |

2 of 2 investments shown.

## Co-investors
- [Ardian](https://shizune.co/investors/profile/ardian) — VC Fund, 2 deals together
- [Auriga Partners](https://shizune.co/investors/profile/auriga-partners) — VC Fund, 2 deals together
- [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 2 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 2 deals together
- [Ace Capital Partners](https://shizune.co/investors/profile/ace-capital-partners) — VC Fund, 1 deal together
- [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Akka Venture invest in?

Akka Venture invests primarily in Medical, Biopharma and Biotechnology startups, most often at Series B and Series C stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Akka Venture?

Public channels for Akka Venture include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Akka Venture?

The team at Akka Venture includes David Jouarisse (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co